The bitcoin halving cycle is already halfway through, with the price increase lagging behind previous cycles.
According to ChainCatcher, citing a report from CoinDesk, the current Bitcoin halving cycle is over halfway complete. The block reward has dropped to 3.125 BTC, the inflation rate is below 1%, and total supply continues to approach the fixed cap of 21 million units.
Since the 2024 halving, Bitcoin's price has increased by about 15%, a lower rate compared to previous halving cycles. This reflects gradually decreasing price volatility as Bitcoin adoption rises and the market matures. The current cycle is expected to conclude in 2028, with halving events occurring every 210,000 blocks, approximately once every four years.
Data shows that Bitcoin reached an all-time high of around $126,000 in 2025, later retracing to $60,000. Recently, the price has recovered to nearly $75,000. The current market focus is that if the price breaks above $75,500, it could trigger the liquidation of about $200 million in short positions, further driving price movement.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Uniswap.com Domain Story Resurfaces After SBF Purchase Claim
A key leap toward the internationalization of the Korean won: The Bank of Korea launches a trial run of its 24/7 international settlement system, with full deployment set for January next year.
The Bank of Korea officially launched the trial operation of the "BOK Won International Payment Network" on Monday local time.
Offshore oil and gas module equipment company VME (VME.US) aiming for Nasdaq listing, plans to raise up to 30 million USD
Offshore oil and gas process module and separation equipment company VME Companies has applied for an IPO on Nasdaq, aiming to raise up to $30 million, with Kingswood as the sole bookrunner.
Hypertension drug developer Retension (RTSN.US) applies for US listing, plans to raise $58 million.
U.S. hypertension drug developer Retension Pharmaceuticals filed documents with the SEC last Friday, planning to raise up to $58 million through an initial public offering (IPO).
Crypto prices
More
